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Key points
• The branched-chain amino acid (BCAA) leucine acts as both a ‘trigger’ for the initiation of
protein synthesis, and as a substrate for newly synthesized protein.
• As a BCAA, leucine can bemetabolized within skeletal muscle, leaving open the possibility that
leucine metabolites might possess anabolic properties.
• One metabolite in particular, β-hydroxy-β-methylbutyrate (HMB), has shown positive effects
on lean body mass and strength following exercise, and in disease-related muscle wasting, yet
its impact on acute human muscle protein turnover is undefined.
• We report here that HMB stimulates muscle protein synthesis to a similar extent to leucine.
HMB was also found to decrease muscle protein breakdown.
• Our observation thatHMBenhancesmuscle protein anabolismmaypartly (orwholly) underlie
its pre-defined anabolic/anti-catabolic supplemental efficacy in humans.
Abstract Maintenance of skeletal muscle mass is contingent upon the dynamic equilibrium
(fasted losses–fed gains) in protein turnover. Of all nutrients, the single amino acid leucine (Leu)
possesses the most marked anabolic characteristics in acting as a trigger element for the initiation
of protein synthesis.While themechanisms by which Leu is ‘sensed’ have been the subject of great
scrutiny, as a branched-chain amino acid, Leu can be catabolized within muscle, thus posing the
possibility that metabolites of Leu could be involved in mediating the anabolic effect(s) of Leu.
Our objective was to measure muscle protein anabolism in response to Leu and its metabolite
HMB. Using [1,2-13C2]Leu and [2H5]phenylalanine tracers, and GC-MS/GC-C-IRMSwe studied
the effect of HMB or Leu alone on MPS (by tracer incorporation into myofibrils), and for HMB
we also measured muscle proteolysis (by arteriovenous (A–V) dilution). Orally consumed 3.42 g
free-acid (FA-HMB) HMB (providing 2.42 g of pure HMB) exhibited rapid bioavailability in
plasma and muscle and, similarly to 3.42 g Leu, stimulated muscle protein synthesis (MPS; HMB
+70% vs. Leu +110%). While HMB and Leu both increased anabolic signalling (mechanistic
target of rapamycin; mTOR), this was more pronounced with Leu (i.e. p70S6K1 signalling
≤90min vs. ≤30min for HMB). HMB consumption also attenuated muscle protein breakdown
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(MPB; −57%) in an insulin-independent manner. We conclude that exogenous HMB induces
acute muscle anabolism (increased MPS and reduced MPB) albeit perhaps via distinct, and/or
additional mechanism(s) to Leu.
(Resubmitted 11 February 2013; accepted 25 March 2013; first published online 3 April 2013)
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Abbreviations 4EBP1, eukaryotic initiation factor 4E binding protein 1; α-KIC, α-ketoisocaproate; AA,
amino acid; AKT, protein kinase B; APE, atom percent excess; BCAA, branched-chain amino acid;
BCAT, branched-chain aminotransferase; BCKDH, branched-chain α-ketoacid dehydrogenase; Ca-HMB, calcium
β-hydroxy-β-methylbutyrate; EAA, essential amino acid; FA-HMB, free acid β-hydroxy-β-methylbutyrate;
FSR, fractional synthetic rate; GC-MS, gas chromatography–mass spectrometry; GC-C-IRMS, gas
chromatography–combustion–isotope ratio mass spectrometry; HMB, β-hydroxy-β-methylbutyrate; HPD,
4-hydroxyphenylpyruvate dioxygenase; LBM, lean body mass; MPB, muscle protein breakdown; MPS, muscle protein
synthesis; mTOR, mechanistic target of rapamycin (previously known as: mammalian target of rapamycin); Leu,
leucine; p70S6K1, 70 kDa ribosomal protein S6 kinase 1.
Introduction
Postabsorptive periods are dominated by negative protein
balance (muscle protein breakdown (MPB) exceeds
muscle protein synthesis (MPS)) that can only be reversed
by food intake. This ‘anabolic’ shift towards a positive
protein balance is principally driven via a brief (∼2 h)
but substantial (∼3-fold) postprandial elevation in MPS
(Atherton et al. 2010a), with a small (∼50%) contribution
from MPB depression (Wilkes et al. 2009). Consequently,
it follows that adequate nutritional intake is crucial for
maintenance of skeletal muscle mass.
Much work has been undertaken, over several years,
in identifying anabolically active nutrients for skeletal
muscle. Early experiments using stable isotope tracer
techniques in humans showed that feeding a mixed
macronutrient meal approximately doubled rates of MPS
(Rennie et al. 1982). Subsequent studies infusing only
amino acid (AA) mixtures confirmed the crucial role
of essential AAs (EAAs) as the principal drivers of
nutritionally stimulated MPS (Bennet et al. 1989). These
studies were further refined where robust stimulation of
MPS was observed with intravenous flooding doses of the
single EAAs phenylalanine, valine and leucine (Leu; Smith
et al. 1992, 1998). Since then a plethora of data, from both
pre-clinical studies (Anthony et al. 2001; Suryawan et al.
2008) and human studies (Churchward-Venne et al. 2012)
have established Leu as one of the most potent EAAs in
terms of stimulating MPS. Indeed, in pre-clinical models,
Leu is often used as a paradigm for stimulating muscle
protein synthesis within the field of skeletalmuscle protein
metabolic research (Anthony et al. 2000a,b, 2001; Norton
et al. 2012). Further underlining the integral role of Leu
are studies showing that, of all the EAAs, Leu initiates
the greatest ‘anabolic’ signalling responses – ostensibly
through the mTORc1–p70S6K1 pathway (Atherton et al.
2010b). It is on this basis that Leu has been suggested as a
direct modulator of MPS, in addition to the more obvious
role as a substrate.
As a branched-chain amino acid (BCAA), Leu
is transaminated in muscle by branched-chain
aminotransferase (BCAT) to α-ketoisocaproate (α-KIC)
before decarboxylation to isovaleryl-CoA by the
mitochondrial enzyme branched-chain α-ketoacid
dehydrogenase (BCKDH), then finally forming Acyl-CoA
derivatives and entering the citric acid cycle. However,
in the liver, an alternative metabolic fate for Leu has
been shown wherein the cytosolic enzyme α-KIC
dioxygenase (or 4-hydroxyphenylpyruvate dioxygenase
(HPD); Van Koevering & Nissen, 1992) generates
β-hydroxy-β-methylbutyrate (HMB) from Leu. This
enzyme has been shown to be expressed in skeletal
muscle, in addition to liver and kidney (Fig. 1), this leaves
open the question as to whether metabolites of Leu could
have direct anabolic effects within muscle. Although it
has been scantily investigated and often trialled under
poorly controlled experimental conditions for defining
the effector (for example, providing Leu metabolites
with other AAs), metabolites of Leu, HMB in particular,
have been shown to enhance gains in muscle mass and
strength. For example, on supplementation with 3 g of
HMB during intense resistance exercise training (RET)
for 3 weeks, healthy, untrained young men have shown a
tendency to increase lean body mass (LBM) and increase
strength when compared to a placebo-treated group
(Nissen et al. 1996). Furthermore, a study in which
elderly women received a supplement containing 2 g
HMB plus 1.5 g of lysine and 5 g of arginine for 12 weeks
revealed significantly greater strength gains and a trend
for increased LBM in the supplemented group (Flakoll
et al. 2004).
Indications from rodent and cell culture models are
that HMB stimulates MPS in a similar fashion to Leu,
that is through the mTOR–p70S6K1 pathway (Eley et al.
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2007). Intriguingly, HMB can rescue depressions of MPS
under both catabolic (e.g. elevated lipopolysaccharide
(LPS), cytokines) and also under normal conditions
throughattenuatingdepressions in activityof themTORc1
pathway (Eley et al. 2007). Moreover, HMB has also
been shown to attenuate catabolism, reducing MPB via
suppression of the ubiquitin-proteasome system (Eley
et al. 2008), and by inhibition of myonuclear apoptosis
by antagonizing mitochondrial-associated caspases (Hao
et al. 2011). Some of these data have translated to human
models of muscle catabolism such as: AIDS (Clark et al.
2000), cancer (May et al. 2002) and COPD (Hsieh et al.
2006). Collectively, these data support the notion that
HMB could mediate its anabolic or anti-catabolic effects
through acutely modulating muscle protein turnover.
To date, no study has investigated the possibility that
HMB could represent an anabolic metabolite of Leu
(responsible for acute effects on protein turnover). In this
study we aimed to remedy that by studying the effects of
HMB on human muscle protein turnover and compare
this with Leu. Our hypotheses were: (i) HMB provision
would acutely stimulate MPS (ii) HMB would stimulate
MPS through mechanisms similar to its precursor, Leu,
and (iii) HMB would also acutely depress MPB.
Methods
Ethical approval
Ethical approval was obtained from the University of
Nottingham Medical School Ethics Committee and the
Hamilton Health Sciences Research Ethics Board at
McMaster University, with all studies being carried out
in accordance with the Declaration of Helsinki. All
volunteers were health-screened prior to participation,
before providing written informed consent.
Subject characteristics and study design
Healthy young men (HMB study group: n= 8, mean age
22± 1 years,mean bodymass index (BMI) 23± 1 kgm−2;
Leu study group: n= 7, mean age 21± 0.3 years, BMI
25± 0.6 kgm−2), who were recreationally active but not
involved in a formal training programme, were recruited
to participate in the study. The two arms of the study were
performed on different sites (Leu: McMaster University,
Hamilton,Canada;HMB:University ofNottingham,UK),
however both groups were recruited based on the same
criteria, and did not differ significantly in age or BMI.
The Leu and HMB studies differed slightly in that while
both MPS and MPB were measured in the HMB study
(Fig. 2A), only MPS was measured in the Leu feeding
study (Fig. 2B). We chose not to measure MPB in the Leu
study primarily due to the confounding factor of insulin
secretion associated with Leu, since studies using large
doses of AAs have failed to show an effect on MPB when
insulin is clamped (Bennet et al. 1990; Greenhaff et al.
2008). Therefore we chose not to place the added burden
of femoral lines on the subjects in the Leu study.Moreover,
our principal focus was on delineating the anabolic effects
of HMB, particularly in relation to MPS (the principal
driver of nutrient-induced skeletal muscle anabolism).
Volunteerswere asked to refrain fromheavy exercise for the
72 h before the study, and to fast from the night before the
study, drinking only water ad libitum. On the morning
of the study (∼08.30 h), subjects had an 18 g cannula
inserted into the antecubital vein of one arm for tracer
infusion, a retrograde 14 g cannula inserted to sample
arterialized blood from the dorsal capillary bed of the
hand (using the ‘hot hand’ method), and – in the HMB
study only – had blood-sampling catheters inserted into
the common femoral vein. A primed, continuous infusion
(0.7 mg kg−1 prime, 1 mg kg h−1 continuous infusion) of
[1,2-13C2]Leu tracer (99 Atoms%, Cambridge Isotopes
Limited, Cambridge, MA, USA) – and in the HMB study
[2H5]phenylalanine (0.3 mg kg−1 prime, 0.6 mg kg h−1
continuous infusion) – was started (at t = −2.5 h) after
the first biopsy and maintained until the end of the
study (+2.5 h). During the first 2.5 h period we gathered
‘baseline’ measurements. The subjects then drank either
3.42 g of a buffered and flavoured free-acid HMB solution
(courtesyofMetabolicTechnologies, Inc.,Ames, IA,USA),
which provided 2.42 g of HMB (solution: ∼70.8% HMB,
29.2% buffering and flavouring), or 3.42 g of L-Leu along
with ∼400ml of water, such that we were able to gather
measures of the effects of HMB or Leu over the next 2.5 h.
Precise timings of blood samples and muscle biopsies for
the HMB and Leu studies can be seen in Fig. 2A and B.
Muscle biopsies (∼200mg) were taken from the vastus
lateralis, under sterile conditions using a local anaesthetic
(1% lidocaine).
Analytical techniques
Blood samples were collected in anticoagulant pre-treated
tubes and stored on ice before being separated at 2000× g
for 20min and the plasma supernatant decanted and
stored at −80◦C until later analyses. The muscle biopsies
were washed in ice-cold phosphate-buffered saline,
quickly separated from visible fat and connective tissue,
flash-frozen in liquid nitrogen and stored for later analyses
at –80◦C. All analyses were performed at the University
of Nottingham, with the exception of intracellular AA
concentrations which were performed at McMaster
University, Hamilton, and plasma/intramuscular HMB
concentrations, which were performed by Metabolic
Technologies Inc.
C© 2013 The Authors. The Journal of Physiology C© 2013 The Physiological Society
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Plasma glucose and insulin concentrations
Postabsorptive plasma glucose concentrations were
measured using an ILab 300 Plus Chemistry Analyser
(Instrumentation Laboratory,Warrington, UK), and both
fasted and postprandial plasma insulin concentrations
were measured using undiluted samples on a
high-sensitivity ELISA (DRG Instruments GmbH,
Marburg, Germany).
Plasma and intracellular amino acid concentrations
For plasma samples, equal measures of plasma and
sulfosalicyclic acid (containing 500 pmolμl−1 norleucine
as an internal standard) were mixed and incubated at 4◦C
for 20min, separated at 13,000× g for 5 min at−4◦C and
the supernatant was passed through a filter (0.22μmpore
size) before being analysed on a dedicated amino acid
analyser (AAA; Biochrom 30: Biochrom, UK) utilizing
a lithium buffer separation (Atherton et al. 2010a). All
AA concentrations were determined by comparison to a
standard sample and with use of the internal standard.
Intracellular amino acids were prepared and analysed by
HPLC as previously described (Glover et al. 2008).
Plasma and intramuscular HMB concentrations
Plasma HMB was analysed by gas chromatography–mass
spectrometry (GC-MS) as previously described (Nissen
et al. 1990). Muscle HMB was analysed using a modified
approach based on the plasma analyses. Briefly, ∼100mg
of muscle tissue was transferred into a 12× 75mm plastic
tube with internal standard. In addition, 0.5 ml of 3 N HCl
and 0.5 ml of ultrapure H2O was added to the tube, and
the contents were homogenized by using tissue homo-
genizer (Tissue Tearor, Biospec Products, Inc, Bartsville,
OK, USA) for 1 min at 20,000 rev min−1. The homo-
genized contents were transferred to a 25× 150mm glass
culture tube and extracted with ethyl ether. The HMBwas
then back-extracted into 0.1 Mphosphate buffer, dried and
analysed by GC-MS as for plasma.
Reverse-transcriptase polymerase chain reaction
(RT-PCR) for HPD mRNA
Total RNA was isolated from human muscle or mouse
liver kidney and skeletal muscle using TRI reagent
(Sigma Aldrich, Poole, UK) and quantified with
spectrophotometric analysis. cDNA was synthesized
from 1μg of total RNA using an iScript cDNA synthesis
kit (Bio-Rad, Hemel Hempstead, UK). The cDNA
(2μl) was amplified using iQ SYBR Green Supermix
(Bio-Rad, Hemel Hempstead, UK) and the following
primers, designed for the human HPD (5′→3′):
forward: CCCTGGAACAAAGAGATGGGCGAT;
reverse: GATTTTGGCGCCCCGTTCCC and mouse:
forward TCTGGTCCGTGGACGACACG; reverse
TCCCTCAAGTGGCGGATTGCTG were used to
determine gene expression of HPD. Amplification
specificity was confirmed by running PCR temperature
gradients with PCR products subject to melt-curve
analysis and visualization on a 2% ethidium
bromide-containing agarose gel to validate the product
matched the predicted amplicon size.
Immunoblotting procedures
Immunoblotting was performed as previously described
(Atherton et al. 2010b). Briefly, ∼30mg of muscle
was homogenized in ice-cold homogenization buffer
(50mm Tris-HCl (pH 7.4), 50 mm NaF, 10mm
β-glycerophosphate disodium salt, 1 mm EDTA, 1mm
EGTA, 1mm activated Na3VO4 (all Sigma-Aldrich,
Poole, UK)) and a complete protease inhibitor cocktail
tablet (Roche, West Sussex, UK) at 10μlμg−1 of
tissue. Homogenates were rotated for 10min and the
supernatant collected by centrifugation at 13,000× g
for 5 min at 4◦C. The supernatant (sarcoplasmic
fraction) was used for immunoblot analysis and
the pellet representing the myofibrillar fraction was
stored at −80◦C until subsequent MPS analysis (see
Measurement of myofibrillar MPS). Sarcoplasmic protein
concentrations were determined using a NanoDrop
ND1000 spectrophotometer (NanoDrop Technologies,
Inc., Wilmington, DE, USA) and adjusted to 1μgμl−1
in 3× Laemmli buffer. Each sample was loaded onto
pre-cast 12% Bis-Tris Criterion XT gels (BioRad,
Hemel Hempstead, UK) at 10–15μg per lane and
separated electrophoretically at 200 V for 1 h. Proteins
were then wet-transferred at 100 V for 1 h onto poly-
vinylidene difluoride (PVDF) membranes (0.22μm pore
size), blocked for 1 h in 2.5% skimmed milk in
1× Tris-buffered saline/Tween-20 (TBS-T), and then
incubated in primary antibodies (1:2000 dilution in 2.5%
BSA in TBS-T) rocking overnight at 4◦C: AKTSer473,
eEF2, eEF2Thr56, eIF2αSer51, Beclin 1, 4EBP1Thr37/46,
eIF4E, GAPDH (New England Biolabs, Hertfordshire,
UK), p70S6K1Thr389, Cathepsin L, Calpain 1, Caspase 3
(Abcam, Cambridge, UK), 4EBP1Ser65/Thr70 (Santa
Cruz Biotechnology, Inc., Santa Cruz, US), MuRF1,
Mafbx/Atrogin 1 (ECM Biosciences, Versailles, KY, USA).
Membranes were subsequently washed 3× 5min in
TBS-T, incubated in HRP-conjugated secondary anti-
body (New England Biolabs, Hertfordshire, UK; 1:2000
in 2.5% BSA in TBS-T) at room temperature for 1 h,
before the last 3×5minwashes inTBS-T.Membraneswere
exposed to Chemiluminescent HRP Substrate (Millipore
Corporation, Billerica, MA, USA) for 5min and bands
C© 2013 The Authors. The Journal of Physiology C© 2013 The Physiological Society
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quantified by Chemidoc XRS (BioRad, Hertfordshire,
UK). Software measures were taken to prevent pixel
saturation and protein loading anomalies were corrected
to total GAPDH, total eIF4E or Coomassie total protein.
Plasma AA labelling
To determine labelling (atom percent excess; APE) and/or
concentrations of arterialized venous and venous Leu,
phenylalanine, and α-ketoisocaproate (α-KIC): briefly,
plasma protein was precipitated using 100% ethanol and
the quinoxalinol KIC derivative formed then extracted
into ethyl acetate, dried down, and derivatized to its
t-butyldimethylsilyl (tBDMS) -quinoxalinol form. The
aqueous layer, containing the amino acids was dried
down and the tBDMS derivative of Leu and phenylalanine
formed. Enrichments were then measured by GC-MS
by selected ion-monitoring (SIM), m/z 259, 261 for
α-KIC, 302, 304 for Leu and 234, 236, 239 for
phenylalanine. Concentrations for plasma phenylalanine
were determined using 2H2 phenylalanine, with reference
to a standard curve.
Measurement of myofibrillar MPS
The pellet from the immunoblot preparation was washed
three times with homogenization buffer (see Immuno-
blotting procedures) and 0.3 M NaOH was added in
order to facilitate the separation of the soluble myo-
fibrillar fraction from the insoluble collagen fraction by
subsequent centrifugation. The myofibrillar fraction was
then removed and precipitated using 1 M perchloric acid
(PCA) and pelleted by centrifugation. The myofibrillar
pellet was then washed twice with 70% ethanol and
the protein-bound AAs were released by acid hydro-
lysis using 0.1 M HCl and 1ml of Dowex ion-exchange
resin (50W-X8-200) heated overnight at 110◦C. AAs
were further purified by ion-exchange chromatography
on Dowex H+ resin columns before being eluted with
NH4OH and derivatized to their N-acetyl-N-propyl
esters. The samples were analysed using capillary
gas chromatography–combustion–isotope-ratio mass
spectrometry (GC-C-IRMS) on a Delta Plus XL (Thermo
Fisher Scientific, Hemel Hempstead, UK) using our
standard techniques (Kumar et al. 2009). The fractional
synthetic rate (FSR) of the myofibrillar proteins was
calculated using a standard precursor–product paradigm:
FSR (%h−1) = δE m/E p × (1/t) × 100,
where δEm is the change in the [1,2-13C2]Leu enrichment
in atoms per excess (APE) between subsequent biopsies,
separated by the time period (t), and Ep is the mean
enrichment over the same time period (t) of the precursor
for protein synthesis, i.e. venous plasma α-KIC was used
as a proxy for leucyl-tRNA, the immediate precursor for
protein synthesis (Watt et al. 1991).
Measurement of MPB
Legmuscleproteinflux (muscleproteinbreakdown,MPB)
was calculated as previously described by arteriovenous
(A–V) dilution of the [2H5]-phenylalanine tracer (Bennet
et al. 1990):
MPB (μmol Phe (100 g leg)−1 min−1) = [(E a/E v) − 1]
×Ca × BF,
Where Ea and Ev are the steady state [2H5]phenylalanine
enrichment values of arterialized and venous samples,
respectively, Ca is the mean [2H5]phenylalanine
concentration in arterialized plasma, and BF is arterial
blood flow in ml leg−1, adjusted for plasma using the
haematocrit.
Statistical analyses
Descriptive statistics were produced for all data
sets and checked for normal distribution using a
Kolgomorov-Smirnov test. Normal distribution was
accepted if P> 0.05. Following correction for loading
anomalies, protein phosphorylation data were normalized
to the fasted time point, which was itself normalized to
a mean of 1 to retain data variance. Graphs are pre-
sented as means± SEM with differences detected with a
two-way measures analysis of variance with Bonferroni
correction, or on a pairwise t test basis for HMB MPB
data (Graph Pad, Version 5, La Jolla, San Diego, CA,
USA). Statistically significant results were designated with
notations according to the figure legends where the
statistical tests indicated that the threshold of P < 0.05
was passed.
Figure 1. Gene expression of HPD
Upper panel, mouse tissues; lower panel, human skeletal muscle,
with standard RT-PCR temperature gradient program shown for
lower panel.
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Results
Effects of oral HMB or Leu on plasma HMB, Leu
and insulin concentrations
With HMB ingestion, fasted plasma HMB concentrations
of 5.1± 1μM increased to 408± 27μM (Fig. 3A) by
30min and remained significantly elevated over the
basal value by the end of the study (275± 12μM
150min post HMB consumption; P < 0.001). With Leu
ingestion, HMB concentrations in plasma were unaltered
until 150min whereby HMB concentrations had risen
modestly from 3.2± 0.6 to 10.3± 3.5μM (P < 0.05).
With HMB ingestion, plasma Leu concentrations
were unaltered throughout (0 min 146± 3 versus
142± 3μM 30–150min). After Leu ingestion, plasma Leu
concentrations (fasted: 142± 5μM) increased by 30min
(495± 28μM; P < 0.01) and remained significantly
elevated at 60min (375± 32μM; P < 0.01) before
returning to values not statistically different from
those of the fasted condition (Fig. 3B). Plasma insulin
concentration remained unaltered in response to HMB
consumption (post HMB study mean 5.9± 1mU l−1;
Fig. 3C). However, in response to Leu, plasma insulin
had increased from baseline (6± 2mU l−1) by 30min
(10± 2mU l−1; P < 0.05) thereafter returning to values
not different from baseline (Fig. 3C).
Effects of oral HMB or Leu on intramuscular HMB, Leu
and EAA concentrations
Fasted concentrations of intramuscular HMB
(7± 3μmol l−1) were increased after oral HMB
consumption (150min: 96± 13μmol l−1; P < 0.01)
but were not detectably altered after Leu consumption
Figure 2. Study designs for assessing the anabolic effects of HMB (A) and Leu (B)
C© 2013 The Authors. The Journal of Physiology C© 2013 The Physiological Society
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(Fig. 4A). While oral HMB consumption did not
affect intramuscular concentrations of Leu or total
EAAs, Leu consumption increased intramuscular
Leu concentrations from 120μmol l−1 at basal to
167± 8μmol l−1 at 150min (P < 0.05; Fig. 4B) without
significantly increasing summed EAA concentrations.
Figure 3. Plasma HMB (A), Leu (B) and insulin (C) in response
to oral HMB (open circle) or Leu (filled circle) consumption
Left y-axis represents scale for HMB group, right y-axis represents
scale for Leu group. Letters indicate statistical significance (P < 0.05):
a = different from respective basal; b = different between groups at
equivalent time-point. Data are presented as means ± SEM.
The effects of oral HMB on MPS and MPB, and of oral
Leu on MPS
The fractional synthesis (FSR) representing MPS of
myofibrillar proteins (Fig. 5A) was increased, from
fasted values of 0.043± 0.004 to 0.073± 0.01% h−1,
Figure 4. Intramuscular concentrations of HMB (A), EAA (B)
and Leu (C) in response to oral HMB (open circle) or Leu (filled
circle) consumption
Dashed line in A indicates intramuscular HMB concentration was
below detection limit. Letters indicate statistical significance
(P < 0.05): a = different from respective basal; b = different
between groups at equivalent time point. Data are presented as
means ± SEM.
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150min after the HMB feed (∼70% P< 0.05). Leu
provision increased myofibrillar FSR (Fig. 4A) from a
basal rate of 0.042± 0.007 to 0.088± 0.005% h−1 over
the 2.5 h post-feeding period (∼110%; P < 0.01). The
effects of HMB and Leu on MPS were not statistically
different (P = 0.12). Over the same time period, HMB
consumption reduced leg proteolysis (an index of MPB;
Fig. 5B) from 12± 4 to 5± 1 μmol Phe l−1.min−1
(∼57%, P< 0.05). To elucidate a potential mechanism
regulating this reduced leg proteolysis with HMB,
the abundance of a number of molecular markers of
proteolytic pathways such as:MuRF1 andMafbx/Atrogin1
(ubiquitin-proteasomal), Beclin 1 (autophagy),
Cathepsin L (lysosomal), Calpain 1 (calcium dependent
protease) were measured using Western blotting. There
were no changes observed in any of these targets (Fig. 6),
with no active forms of Caspase 3 detected either (data not
shown).
Figure 5. Myofibrillar FSR in response to oral HMB (open
circle) or Leu (filled circle) consumption (A) and leg proteolysis
in response to HMB consumption (B)
Letters indicate statistical significance (P < 0.05): a = different from
respective basal (a P < 0.05; aa P < 0.01). Data are presented as
means ± SEM.
The effects of HMB and Leu on mTORC1 signalling
Phosphorylation of AKTSer473 did not alter in response
to HMB. In contrast, Leu consumption resulted in
increased concentrations ofAKTSer473 (∼36%,P < 0.05)
30min after consumption (Fig. 7A). The phosphorylation
of p70S6K1 increased similarly in both HMB
(∼56%) and Leu (∼45%, P < 0.05) groups at 30min
(Fig. 7B). However, by the 90min time point increased
p70S6K1 phosphorylation was maintained (∼71%)
only in the Leu group. After 30min ingestion of
HMB and Leu, there was a modest increase in
4EBP1Ser65/Thr70 phosphorylation (∼27% and ∼18%,
respectively; P < 0.05), but not for phosphorylation at
its Thr37/46 sites (Fig. 7D). As with p70S6K1, increased
phosphorylation of 4EBP1Ser65/Thr70 was maintained
with Leu at 90min (∼19%; P < 0.05) but not with HMB
(Fig. 7C). Phosphorylation of eIF2αSer51 and eEF2Thr56
did not change in either the HMB or Leu groups (Fig. 7E
and F).
Discussion
Nutrient-mediated increases in MPS preserve the net
muscle protein equilibrium (fasted losses vs. fed gains) to
ensure muscle mass remains constant. Much of this effect
has been attributed to the single EAA Leu (Kimball &
Jefferson, 2006). Although the majority of focus has been
on identifying proximal signalling mechanisms by which
BCAA, and particularly Leu stimulated MPS, Leu is also
able to undergo catabolism in muscle and consequently
we were interested in exploring the possibility that Leu
metabolites could possess anabolic attributes. With pre-
vious evidence in the literature suggesting HMB may
possess anabolic potential, we consequently focused on
the role of HMB.
We report that oral consumption of HMB in
free-acid form (FA-HMB), rapidly elevated plasma
and intramuscular HMB bioavailability from fasting
concentrations. We chose FA-HMB over the more
commonly used calcium-HMB (Ca-HMB) principally
because of the more favourable bioavailability kinetics
(Fuller & Sharp, 2011). When comparing the effects of
HMB vs. Leu on MPS, we found a robust stimulation
(HMB ∼70% vs. Leu ∼110%). To place this size of
response toHMBorLeu in contextwith amore substantial
feeding regime, our previous study of feeding 48 g whey
protein to young men (Atherton et al. 2010a) resulted in
∼2.5-fold increases in MPS over a 1.5 h period post-feed,
before MPS returned to baseline over the next period
measured (1.5–2.5 h). If this response were to be directly
comparedwith this presentLeuandHMBwork,madeover
a 2.5 h measurement period, then overall prandial protein
accretion via increases in MPS would be roughly similar
(note thatMPS is calculated as incorporation/time). These
C© 2013 The Authors. The Journal of Physiology C© 2013 The Physiological Society
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facts are striking and imply that it is possible to robustly
increaseMPS responses to nutrition by supplying complex
mixtures of EAAs but also Leu, and even HMB, alone, at
least until EAA and NEAA substrate depletion becomes
rate limiting for MPS (Churchward-Venne et al. 2012).
Notably, there was tendency for the rates of MPS to be
greaterwith Leu vs. those seenwithHMB(P = 0.12); these
data imply thatHMB is slightly less effective in stimulating
MPS than Leu, at least at presently administered doses.
Due to its insulin secretagogue properties (Zhou
et al. 2010), Leu, as expected, induced a transient
spike in plasma insulin at 30min after consumption.
On this basis, some might attribute a portion of the
Leu-mediated increases inMPS to insulin. However, when
AAs are infused with insulin clamped at post-absorptive
concentrations (∼5μUml−1) the MPS response is not
dampened (Greenhaff et al. 2008), suggesting that insulin
is at best permissive for the stimulation ofMPS.Moreover,
HMB did not affect insulin secretion despite generating
comparable protein synthetic responses to that of Leu.
Therefore, as we have identified that HMB, unlike Leu,
is not an insulin secretagogue, it is unlikely that insulin
is responsible for the changes in MPS we observe with
Leu.
Ingestion of Leu induced an ‘anabolic’ signalling
response in AKT, p70S6K1 and 4EBP1 (at least in as much
as phosphorylation indicates activation of these proteins)
that was of a lesser amplitude (∼71% vs. ∼112% increase
at 90min post-feeding) and duration than in our pre-
vious study involving the feeding 48 g of whey protein
isolate (Atherton et al. 2010a). The lesser response may
have been due to a lower dose of Leu (3.42 g in the present
study vs. 6 g in the whey protein study) or possibly that
other EAAs are required to maximize signalling through
mTORc1 (Atherton et al. 2010b; Churchward-Venne et al.
2012). Regardless, this raises further caution in terms of
interpreting changes in mTORc1 signalling amplitude as
a reliable proxy of MPS (Greenhaff et al. 2008).
HMB-induced anabolic signalling was even less distinct
than that seen with Leu since there was no modulation
of AKT and a reduced duration of p70S6K1 and 4EBP1
signalling (∼30min vs. 30–90min after Leu) after HMB
consumption.The lackofAKTmodulationwithHMBwas
almost certainly due to the fact that HMB, unlike Leu, did
not promote insulin secretion (Fig. 3C). This is because
EAAs signal through distinct proximal insulin receptor
response elements such as the Rag GTPases (Sancak
et al. 2008) or leucyl tRNA synthetase (Han et al. 2012),
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consumption
Data are presented as mean ± SEM.
C© 2013 The Authors. The Journal of Physiology C© 2013 The Physiological Society
2920 D. J. Wilkinson and others J Physiol 591.11
whereas insulin signals though the canonical insulin
receptor substrate–phosphoinositide-3-kinase–AKT
(IRS-1-PI3K-AKT) signalling pathway. The stimulation
of MPS through mTORc1-signalling following HMB
exposure is in agreement with pre-clinical studies
(Eley et al. 2008). However, the reduced magnitude of
signalling compared to Leu suggests, at least in context
of the quantities provided, that Leu is more a potent
signalling agent than HMB. One possibility is that
multiple metabolites of Leu are capable of stimulating
MPS such as α-KIC (Escobar et al. 2010). Nonetheless,
as the overall MPS response was similar, this cellular
signalling distinction did not translate into statistically
distinguishable anabolic effects in our primary outcome
measure of MPS.
Furthermore, there was clear divergence in the
amplitude of phosphorylation for 4EBP1 (at Thr37/46 and
Ser65/Thr70) and p70S6K (Thr389) in response to both
Leu and HMB, with the latter showing more pronounced
and sustained phosphorylation. It has been shown that
the phosphorylation of 4EBP1 is a two-step process: while
mTORphosphorylation at Thr37 and Thr46 does not pre-
vent the binding of 4EBP1 to eIF4E, it is thought to prime
4EBP1 for subsequent phosphorylation at Ser65/Thr70
(Gingras et al. 1999) which then promotes eIF4F complex
assembly. While we were unable to detect such ‘priming’
(Thr37/46) phosphorylation on 4EBP1 after Leu or HMB,
we did detect significant increases on Ser65/Thr70, which
perhaps mediated increases in MPS though assembling
eIF4F and thus promoting cap-dependent translation.
Also, since previous work by us and others revealed
discrepancies in the amplitude of 4EBP1 and p70S6K
phosphorylation following resistance exercise (Kumar
et al. 2009; Holm et al. 2010) and nutrition (Fujita
et al. 2007; i.e. phosphorylation of p70S6K being more
pronounced than 4EBP1), this is perhaps why p70S6K,
rather than 4EBP1, is most commonly adopted as a proxy
for mTOR signalling.
Interestingly, although orally supplied HMB produced
no increase in plasma insulin, it caused a depression
in MPB (−57%). Normally, postprandial decreases in
MPB (of ∼50%) are attributed to the nitrogen-sparing
effects of insulin since clamping insulin at post-absorptive
concentrations (5μUml−1) while continuously infusing
AAs (18 g h−1) did not suppress MPB (Greenhaff et al.
2008), which is why we chose not to measure MPB in
the Leu group, due to an anticipated hyperinsulinaemia
(Fig. 3C). Thus, HMB reduces MPB in a fashion
0 50 10
0
15
0
0.8
1.0
1.2
1.4
1.6
Leu
HMB
a,b
A
Time (min)
A
K
T 
S
er
47
3 /
 G
AP
D
H
 (A
U
)
0 50 10
0
15
0
0.8
1.2
1.6
2.0
HMB
c a,b
Leu
B
Time (min)
p7
0S
6K
1T
hr
38
9 /
G
AP
D
H
 (A
U
)
0 50 10
0
15
0
0.0
0.5
1.0
1.5
2.0
HMB
Leu
D
Time (min)4E
-B
P
1T
hr
37
/4
6 /
To
ta
l C
oo
m
as
si
e 
(A
U
)
0 50 10
0
15
0
0.0
0.5
1.0
1.5 HMB
Leu
E
Time (min)
p-
eI
F2
S
er
51
/T
ot
al
 C
oo
m
as
si
e 
(A
U
)
0 50 10
0
15
0
0.0
0.5
1.0
1.5
HMB
Leu
F
Time (min)
p-
eE
F2
Th
r5
6 /
To
ta
l e
IF
4E
 (A
U
)
0 50 10
0
15
0
Time (min)
HMB
Leu
c
a
C
4E
-B
P
1S
er
65
/T
hr
70
/ G
AP
D
H
 (A
U
)
0.8
1.0
1.2
1.4
Figure 7. AKTSer473 (A), p70S6K1Thr389 (B), 4EBP1Ser65/Thr70 (C), 4EBP1Thr37/46 (D), eIF2αSer51 (E),
eEF2Thr56 (F) in response to oral HMB (open circle) or Leu (filled circle) consumption
Statistical notations: a = different from respective basal; (P < 0.05), b = different between groups at equivalent
time-point (P < 0.05), c = different from respective basals under both conditions (P < 0.05). Data are presented
as means ± SEM.
C© 2013 The Authors. The Journal of Physiology C© 2013 The Physiological Society
J Physiol 591.11 Effects of leucine and HMB on muscle anabolism 2921
similar to, but independent of, insulin. These findings
are in-line with reports of the anti-catabolic effects
of HMB suppressing MPB in pre-clinical models, via
attenuating proteasomal-mediated proteolysis in response
to LPS (Eley et al. 2008). In attempt to determine the
regulatory mechanism behind this insulin-independent
decrease in MPB with HMB, a number of molecular
targets associated with different proteolytic systems
(the ‘atrogenes’, Beclin 1, Calpain 1, Cathepsin L and
Caspase 3)were examined.However therewerenochanges
in the abundance of protein observed any of these
and we were also unable to detect any changes in
post-translational indicators of proteolytic activity, i.e.
autolytic cleavage of Calpain 1 or detection of active
(cleaved) forms of Caspase 3. These findings are in
agreement with a past study of ours showing that
acute depressions in MPB, under insulin-clamped insulin
conditions, yielded no associations to the abundance
of protein or mRNA of several of these proteolytic
‘marker’ genes (Greenhaff et al.2008).Moreover,while, for
example, the atrogenes (MuRF-1 andMafbx) can robustly
inform upon chronic scenarios of protein catabolism
(sepsis, burns, trauma; Murton et al. 2008) associated
with skeletal muscle atrophy, it would appear they are
not (measurably) sensitive to acute episodic depressions
in MPB with nutrition. Therefore, until protein
kinases/phosphorylation sites of signalling pathways that
inform on acute/nutrition-mediated depressions in MPB
are identified, linking single or multiple MPB-related
pathways defining the mechanisms behind the acute
anti-catabolic effects of HMB/insulin remains intractable.
Nonetheless, our observations set HMB apart fromhyper-
aminoacidaemia which could not suppress MPB in the
absence of hyperinsulinaemia (Greenhaff et al. 2008).
Lastly, we would like to acknowledge a number of
potential study limitations. The groups were studied in
different locations: HMB at the University of Nottingham,
UK and Leu at McMaster University, Canada. Non-
etheless, the protocol used and recruitment criteria
were identical between both groups, with both labs
involved having extensive experience of conducting such
work and all components of analysis were completed
at the University of Nottingham (with the exception of
HMB and intracellular AA concentrations). However, we
are not aware of data to suggest that Europeans and
North Americans respond differently to nutrition (e.g.
leucine); indeed the MPS responses to Leu herein are
identical to those we have published previously (Smith
et al. 1992). We did not control for dietary protein
intake or habitual activity. However, all volunteers were
confirmed as only recreationally active and not in formal
training regimes and we are unaware of data to show
that different habitual protein intake modulates acute
anabolic responses to Leu. Furthermore, it was not
possible from the present study to determine amechanism
for the observed HMB reduction in MPB, despite
measuring the abundance/post-translation modifications
of caspase, calpain, autophagy and proteasomal pathway
gene markers. Whilst we acknowledge these potential
limitations, our work depicts for the first time a
comparison of the acute effects of consumption of Leu
and its metabolite HMB in young men. Consumption of
small amounts (∼2–3 g) of either Leu or its metabolite
HMB resulted in the acute increase of MPS to a degree
comparable to that seen after a mixed meal, with HMB
also suppressing MPB.
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